Tokuyama to acquire JSR's in-vitro diagnostics business

Tokuyama Corporation (TSE:4043) announced that its board has approved the acquisition of JSR Corporation's in-vitro diagnostics and in-vitro diagnostic pharmaceutical materials businesses. The acquisition will be facilitated through the establishment of a new entity, JSR-01 Corporation, which will inherit the target businesses via absorption-type splits. Tokuyama will then acquire all outstanding shares of JSR-01, making it a wholly-owned subsidiary.